

Pharmacy Utilization Meeting

October 14, 2022

Attendees

Linda Coyle (IMS) – absent
Jennifer Stevens (IMS)
David Angelaszek (IMS)
Chuck May (IMS) – absent
Emily Carver (IMS)
Kevin Ward (Georgia)
Randi Rycroft (Idaho)
Serban Negoita (NCI) – absent
Peggy Adamo (NCI)
Marina Matatova (NCI)
Nadia Howlader (NCI) – absent
Jennifer Hafterson (Seattle)
Tiffany Janes (Seattle)
Kaitlin Akif (NCI)

1. Review list of exclusive oncologic agents prescribed prior to dx for 00/01 CTCs
 - Emily sent this to Serban via email on 10/04/2022. Serban was not on the call today so we will postpone discussion to next week.
2. Look at distribution of pharm_flag (yes/no in claims data) by registry
 - Emily presented the results. Results across registries were fairly consistent. No questions or concerns were raised during the meeting.
3. Review creation of cumulative duration and quantity fields that do and do not include the 1 year time restriction
 - Emily presented the hormone results that gave the following counts:
 - Counts of first course agent dispensing events after diagnosis - no 1 year after DX restriction
 - Cumulative duration of all first course agent dispensing events after diagnosis - no 1 year after DX restriction
 - Cumulative quantity of all first course agent dispensing events after diagnosis - no 1 year after DX restriction
 - Counts of first course agent dispensing events after diagnosis - only events within 1 year after DX

- Cumulative duration of first course agent dispensing events within 1 year after diagnosis
 - Cumulative quantity of first course agent dispensing events within 1 year after diagnosis
- Kevin commented that it might be more useful to refine these further and have count, cumulative quantity and cumulative duration for all first course agent dispensing events if the patient had a first course agent dispensing event within the first year after diagnosis (FCOT).
- **Action:** Emily will work on Kevin's request and will break out these fields by DX year as well to account for different periods of times post DX.

4. Review full file documentation for correct wording (first course dispensing event vs FCOT)

- Some edits were made to the descriptions used in the "file content" excel file which describes the augmented data items being produced from the pharmacy data. Careful attention is being paid to the distinction between what is a first course agent what is first course of therapy.
- **Action:** David and Emily will work together to produce formal documentation of the workgroup's efforts that can be shared with the broader community.